AliveDx announces U.S. Food and Drug Administration 510 submission for its MosaiQ AiPlex® Vasculitis assay.

and connect with us on LinkedIn and X.? 

©AliveDx Suisse SA. 2025. The AliveDx logo, AliveDx, MosaiQ and MosaiQ AiPlex, are trademarks or registered trademarks of AliveDx group companies in various jurisdictions. Menus and capabilities are subject to change. Not all methods may be available in all territories.

Robson JC et al. 2022 ACR/EULAR GPA Classification Criteria.Ann Rheum Dis. 2022;81(3):315–320.?  Suppiah R et al. 2022 ACR/EULAR MPA Classification Criteria.Ann Rheum Dis. 2022;81(3):321-326.?  Grayson PC et al. 2022 ACR/EULAR EGPA Classification Criteria.Ann Rheum Dis. 2022;81(3):309-314.?  KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276.?  

Logo: https://mma.prnewswire.com/media/2657402/5489172/AliveDx_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/alivedx-announces-us-food-and-drug-administration-fda-510k-submission-for-its-mosaiq-aiplex-vasculitis-vas-assay-302544959.html